References
1. Nishiga M., Wang D.W., Han Y., Lewis D.B., Wu J.C. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020; 17 (9): 543–58.
2. Libby P., Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020; 41 (32): 3038–44.
3. Guzik T.J., Mohiddin S.A., Dimarco A., et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020; 116 (10); 1666–87.
4. Islam N., Lacey B., Shabnam S., Erzurumluoglu A.M., Dambha-Miller H., Chowell G., et al. Social inequality and the syndemic of chronic disease and COVID-19: county-level analysis in the USA. J Epidemiol Community Health. 2021; jech-2020-215626. DOI: https://www.doi.org/10.1136/jech-2020-215626.
5. Rajagopalan S., Jackson R.B., Narula J. COVID-19 and Emissions: An Opportunity for Sustainable Global Health. European Heart Journal. 2021. 42 (35): 3415–7.
6. Libby P., Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020; 41 (32): 3038–44.
7. Kulick E.R., Canning M., Parikh N.S., Elkind M.S.V., Boehme A.K. Seasonality of Influenza-Like-Illness and Acute Cardiovascular Events Are Related Regardless of Vaccine Effectiveness. J Am Heart Assoc. 2020; 9 (20): e016213. DOI: https://www.doi.org/10.1161/JAHA.120.016213
8. Chow E.J., Rolfes M.A., O'Halloran A., et al. Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults: A Cross-sectional Study. Ann Intern Med. 2020; 173 (8): 605–13.
9. Lombardi C.M., Carubelli V., Iorio A., et al. Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study. JAMA Cardiol. 2020; 5 (11): 1274–80.
10. Haas E.J., Angulo F.J., McLaughlin J.M., et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2020; 2021 (397): 1819–29.
11. Glikson M., Nielsen J.C., Kronborg M.B., et.al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA). European Heart Journal. 2022; 24 (1): 71–164. DOI: https://www.doi.org/10.1093/europace/euab232
12. GenOMICC. GenOMICC.org. URL: https://genomicc.org/
13. Xiao Y., Tang L., Liu Q., Hu X., Fang Z., Zhou S. Rationale and Design of the H-REPLACE Study: Safety and Efficacy of LMWH Versus Rivaroxaban in ChinEse Patients HospitaLized with Acute Coronary SyndromE. Cardiovasc Drugs Ther. 2022; 36 (1): 69–73. DOI: https://www.doi.org/10.1007/s10557-020-07076-9
14. Smits P.C., Frigoli E., Tijssen J., Jüni P., Vranckx P., Ozaki Y., et al. MASTER DAPT investigators. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. Circulation. 2021; 144 (15): 1196–211. DOI: https://www.doi.org/10.1161/CIRCULATIONAHA.121.056680
15. Van Mieghem N.M., Unverdorben M., Hengstenberg C., Möllmann H., Mehran R., López-Otero D., et al. ENVISAGE-TAVI AF Investigators. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med. 2021; 385 (23): 2150–60. DOI: https://www.doi.org/10.1056/NEJMoa2111016
16. Stefanini G.G., Briguori C., Cao D., et al. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. Eur Heart J. 2021. Epub ahead of print.
17. Wood Sh. In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS. TCTMD. 2021. URL: https://www.tctmd.com/news/acs-clopidogrel-monotherapy-after-1-month-dapt-falls-short-stopdapt-2-acs [Date of access: 06.09.2021].
18. Svendsen J.H., Diederichsen S.Z., Højberg S., et.al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. The Lancet. 2021; 398 (10310): 1507–16. URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01698-6/fulltext [Date of access: 06.09.2021].
19. Brignole M., Pentimalli F., Palmisano P., Landolina M., Quartieri F., Occhetta E., et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J. 2021; 42 (46): 4731–9. DOI: https://www.doi.org/10.1093/eurheartj/ehab569
20. Marrouche N.F., Greene T., Dean J.M., Kholmovski E.G., Boer L.M., Mansour M., et al. DECAAF II Investigators. Efficacy of LGE-MRI-guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation: The DECAAF II trial: Study design. J Cardiovasc Electrophysiol. 2021; 32 (4): 916–24.
21. Amulet occluder shows promise against Watchman device in atrial fibrillation. The European Society of Cardiology. 2021. URL: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Amulet-occluder-shows-promise-against-Watchman-device-in-atrial-fibrillation
22. Kario K., Nomura A., Harada N., et.al. Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial. European Heart Journal. 2021; 42 (40): 4111–22. DOI: https://www.doi.org/10.1093/eurheartj/ehab559. URL: https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehab559/6358480?redirectedFrom=fulltext [Date of access: 06.09.2021].
23. Chow C.K., Atkins E.R., Hillis G.S., et.al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. The Lancet. 2021; 398 (10305): 1043–52. DOI: https://www.doi.org/10.1016/S0140-6736(21)01922-X. URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01922-X/fulltext. [Date of access: 06.09.2021].
24. Jin A., Liu K., Labarthe D.R., Feng X., Zhang R., Wang H., et al. Impact of salt substitute and stepwise reduction of salt supply on blood pressure in residents in senior residential facilities: Design and rationale of the DECIDE-Salt trial. Am Heart J. 2020; 226: 198–205.
25. Neal B., Tian M., Li N., Elliott P., Yan L.L., Labarthe D.R., Huang L., Yin X., Hao Z., Stepien S., Shi J., Feng X., Zhang J., Zhang Y., Zhang R., Wu Y. Rationale, design, and baseline characteristics of the Salt Substitute and Stroke Study (SSaSS)-A large-scale cluster randomized controlled trial. Am Heart J. 2017; 188: 109–17.
26. Visseren F.L.J., Mach F., Smulders Y.M., et.al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European Heart Journal. 2021; 42 (34): 3227–37. DOI: https://www.doi.org/10.1093/eurheartj/ehab484. URL: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehab484/6358713. [Date of access: 08.09.2021].
27. Zhang W., Zhang S., Deng Y., et.al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. The New England Journal of Medicine. 2021; 385 (14): 1268–79. DOI: https://www.doi.org/10.1056/NEJMoa2111437. URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2111437. [Date of access: 08.09.2021].
28. Anker S.D., Filippatos B.G., Ferreira J.P., et al., on behalf of the EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure With a Preserved Ejection Fraction. N Engl J Med. 2021; 385: 1451–61.
29. Packer M., Butler J., Filippatos G., Zannad F., Ferreira J.P., Zeller C., Brueckmann M., Jamal W., Pocock S.J., Anker S.D.; EMPEROR Trial Committees and Investigators. Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. Eur J Heart Fail. 2020; 22 (12): 2393–8.
30. Lindenfeld J., Zile M.R., Desai A.S., Bhatt K., Ducharme A., Horstmanshof D., et al.Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. The Lancet. 2021; 398 (10304): 991–100.1.
31. Pitt B., Filippatos G., Agarwal R., Anker S.D., Bakris G.L., Rossing P., et al. FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021; 385 (24): 2252–63. DOI: https://www.doi.org/10.1056/NEJMoa2110956.
32. Desch S., Freund A., Akinet I., et al. Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation. The New England Journal of Medicine. 2021; 385 (27): 2544–53. DOI: https://www.doi.org/10.1056/NEJMoa2101909. URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2101909
33. Skurk C., Rottbauer W., Kessler M., Akin I., Kluge S., Burdelski C., et al. The ACCOST-HH Trial. Eur Heart J. 2020; 41 (45): 4296–8.
34. RIPCORD 2: No Benefit of Systematic FFR vs. Angiography During Diagnostic Angiography. American College of Cardiology. 2021. URL: https://www.acc.org/latest-in-cardiology/articles/2021/08/26/20/08/sun-830am-ripcord-2-esc-2021
35. Halliday A., Bulbulia R., Bonati L.H., et.al. Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy. The Lancet. 2021; 398 (10305): 1065–73. URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01910-3/fulltext#seccestitle10